JAGUAR HEALTH, INC. (JAGX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2018-09-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2018-09-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2018-09-30..
Borrowing debt
Overview →Financial period ending 2018-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2018-09-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2018-09-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2018-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 46.12M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2018-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | $46.12M | (m) |
| 2018-06-30 | (m) | (m) | $0.00 | $10.77M | (m) | (m) | $46.16M | (m) |
| 2018-03-31 | (m) | (m) | $0.00 | $10.88M | (m) | (m) | $50.27M | (m) |
| 2017-12-31 | (m) | (m) | $1.61M | (m) | (m) | (m) | $43.63M | (m) |
| 2017-09-30 | (m) | (m) | $1.80M | (m) | (m) | (m) | $59.99M | (m) |
| 2017-06-30 | (m) | (m) | $2.07M | $835.98K | (m) | (m) | $4.94M | (m) |
| 2017-03-31 | (m) | (m) | $1.99M | $1.33M | (m) | (m) | $3.57M | (m) |
| 2016-12-31 | (m) | (m) | $1.92M | $1.82M | (m) | (m) | $3.56M | (m) |
| 2016-09-30 | (m) | (m) | $1.85M | $2.27M | (m) | (m) | $5.10M | (m) |
| 2016-06-30 | (m) | (m) | $1.47M | $2.69M | (m) | (m) | $7.20M | (m) |
| 2016-03-31 | (m) | (m) | $2.12M | $3.63M | (m) | (m) | $11.98M | (m) |
| 2015-12-31 | (m) | (m) | $1.71M | $4.10M | (m) | (m) | $12.41M | (m) |
| 2015-09-30 | (m) | (m) | $1.45M | $4.46M | (m) | (m) | $16.64M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |